Abstract：
Despite a growing consensus that testing for hereditary thrombophilia (HT) is not recommended in the setting of venous thromboembolism (VTE), such testing is still often requested. We evaluated the effects of HT on the risk of recurrent VTE for patients with lower extremity deep vein thrombosis (DVT).
We conducted a multihospital retrospective study of 867 patients with first-time proximal lower extremity DVT who had undergone testing for HT. Patients with and without HT were compared regarding their VTE recurrence risk via Kaplan-Meier and multivariable analysis.
HT was present in 166 patients (19%). The baseline characteristics were similar between the patients with HT and without HT. No significant difference was found in the recurrence rates between the two groups (HT, 17%; no HT, 15%; P = .345). A Kaplan-Meier survival analysis revealed no significant differences in VTE-free survival between the patients with and without HT (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.77-1.84; P = .421). On multivariable analysis, the presence of HT was not associated with recurrent VTE. A higher body mass index (HR, 1.06; 95% CI, 1.03-1.10; P = .004) and unprovoked DVT (HR, 2.48; 95% CI, 1.69-3.66; P < .001) were risk factors for recurrence.
HT had no significant impact on the recurrence risk for patients with first-time lower extremity DVT. HT test results would, thus, not be expected to change clinical management and should therefore not be requested routinely for patients with DVT.
We conducted a multihospital retrospective study of 867 patients with first-time proximal lower extremity DVT who had undergone testing for HT. Patients with and without HT were compared regarding their VTE recurrence risk via Kaplan-Meier and multivariable analysis.
HT was present in 166 patients (19%). The baseline characteristics were similar between the patients with HT and without HT. No significant difference was found in the recurrence rates between the two groups (HT, 17%; no HT, 15%; P = .345). A Kaplan-Meier survival analysis revealed no significant differences in VTE-free survival between the patients with and without HT (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.77-1.84; P = .421). On multivariable analysis, the presence of HT was not associated with recurrent VTE. A higher body mass index (HR, 1.06; 95% CI, 1.03-1.10; P = .004) and unprovoked DVT (HR, 2.48; 95% CI, 1.69-3.66; P < .001) were risk factors for recurrence.
HT had no significant impact on the recurrence risk for patients with first-time lower extremity DVT. HT test results would, thus, not be expected to change clinical management and should therefore not be requested routinely for patients with DVT.
摘要：
尽管越来越多的共识认为，在静脉血栓栓塞症（VTE）的情况下，不建议进行遗传性血栓症（HT）的检测，这种测试仍然经常被要求。我们评估了HT对下肢深静脉血栓形成（DVT）患者复发性VTE风险的影响。
我们进行了一项多医院回顾性研究，对867例首次接受HT检测的下肢近端DVT患者进行了回顾性研究。通过Kaplan-Meier和多变量分析比较有和无HT患者的VTE复发风险。
166例患者（19%）存在HT。HT患者和无HT患者的基线特征相似。两组复发率无显著差异(HT,17%；无HT，15%；P=.345）。Kaplan-Meier生存分析显示，有和没有HT的患者之间无VTE生存没有显着差异（风险比[HR]，1.19；95%置信区间[CI]，0.77-1.84；P=.421）。在多变量分析中，HT的存在与VTE复发无关.较高的体重指数（HR，1.06；95%CI，1.03-1.10；P=.004）和无端DVT（HR，2.48；95%CI，1.69-3.66；P<.001）是复发的危险因素。
HT对首次下肢DVT患者的复发风险无显著影响。HT测试结果会，因此，预计不会改变临床管理,因此DVT患者不应接受常规治疗.
我们进行了一项多医院回顾性研究，对867例首次接受HT检测的下肢近端DVT患者进行了回顾性研究。通过Kaplan-Meier和多变量分析比较有和无HT患者的VTE复发风险。
166例患者（19%）存在HT。HT患者和无HT患者的基线特征相似。两组复发率无显著差异(HT,17%；无HT，15%；P=.345）。Kaplan-Meier生存分析显示，有和没有HT的患者之间无VTE生存没有显着差异（风险比[HR]，1.19；95%置信区间[CI]，0.77-1.84；P=.421）。在多变量分析中，HT的存在与VTE复发无关.较高的体重指数（HR，1.06；95%CI，1.03-1.10；P=.004）和无端DVT（HR，2.48；95%CI，1.69-3.66；P<.001）是复发的危险因素。
HT对首次下肢DVT患者的复发风险无显著影响。HT测试结果会，因此，预计不会改变临床管理,因此DVT患者不应接受常规治疗.
